C
ContinuumRx
Specialty Infusion Services | ContinuumRx
About ContinuumRx
ContinuumRx provides home and alternate site-based infusion therapies through a joint venture business model with hospital systems. Founded in 2010 after Principle Pharmacy Group sold its management division, the company focuses exclusively on the home infusion market to provide a seamless transition for patients from hospital to home. The company was originally led by Chairman and CEO Chuck Jett and is now led by CEO Keith P. Hartman. Hartman is an experienced pharmacy entrepreneur, having founded and grown retail, compounding, and specialty pharmacies.
The firm partners with health systems to improve post-acute care coordination, reduce hospital readmissions, and lower overall healthcare costs. This model allows hospitals to offer home infusion services without the operational risks of managing it themselves. ContinuumRx's services include a range of infusion therapies such as antibiotics, enteral and parenteral nutrition, immunoglobulins, heart failure therapies, and other specialty biologic medications. Care is available 24/7, with pharmacists and nurses on-call to support patient needs. The company's clients are health systems and hospitals in the Southern U.S., including locations in Alabama, Tennessee, and Virginia. Revenue is generated through these partnerships, which provide a new revenue source for the hospitals and are supported by the company's proprietary reporting platform that tracks therapy compliance and outcomes for payers and physicians.
Through its subsidiary, Continuum Health, the company also operates full-service infusion clinics that offer a private and comfortable setting for patients, differing from typical hospital environments. In 2015, ContinuumRx secured $13.5 million in a financing round led by NewSpring Capital to fund expansion into new markets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Hoover, United States
- Employees
- 70
- Open positions
- 7
- Dealroom signal
- 46.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Infusion, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jul 2015 | $14M | $54M | Undisclosed | — |
| EARLY VC✓Equity / VC | Sep 2012 | $7M | $28M | Health Enterprise Partners · Mitsui Global Investment · Redmont Venture Partners · Stonehenge Capital | — |
Growth signals
Latest recorded traffic for ContinuumRx is 4.2K monthly website visits, up 68% over the last three months. ContinuumRx's team grew 6.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Health Enterprise Partners
Mitsui Global Investment
Redmont Venture Partners
Stonehenge Capital
NewSpring Capital
Other known investors1 additional known investor
Redmont Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ContinuumRx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ContinuumRx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.